Blood Podcast Rapid, high-sensitivity ADAMTS13 assays for TTP; combination CD38/PD-1 blockade in extranodal NK/T-cell lymphoma; a “zombie enzyme” in CREBBP-mutant lymphomas
Jul 10, 2025
Discover groundbreaking rapid assays that enhance the diagnosis of thrombotic thrombocytopenic purpura, minimizing unnecessary treatments. Learn about a powerful combination therapy using CD38 and PD-1 blockade, showing impressive outcomes in relapsed NK/T-cell lymphoma. Dive into a captivating tale of a ‘zombie enzyme’ in CREBBP-mutant lymphomas, and uncover how a bispecific antibody cleverly restores CD40 signaling to help achieve lymphoma cell death.
AI Snips
Chapters
Transcript
Episode notes
Rapid ADAMTS13 Assays Accuracy
- Rapid ADAMTS13 assays can quickly diagnose TTP, reducing unnecessary plasma exchange and other treatments.
- The Hemosyl Accustar CLIA assay shows high sensitivity, specificity, and fast turnaround time under 40 minutes.
Learn Rapid ADAMTS13 Testing
- Physicians should become familiar with rapid ADAMTS13 testing to improve TTP diagnosis.
- Early recognition of severe ADAMTS13 deficiency can save lives, even if many tests are normal.
CD38/PD-1 Combo Effective in ENKTL
- Combining CD38 and PD-1 blockade yields durable responses in relapsed/refractory ENKTL lymphoma.
- Structural variations in PD-L1 may serve as biomarkers predicting response to this combination therapy.